A team of researchers from across five disciplines at MD Anderson recently published the largest prospective study on breast implant associated anaplastic large cell lymphoma (BIA-ALCL), shedding light on the best treatment for patients with this uncommon cancer.
“This study underscores the critical importance of a standard treatment approach with a multi-team evaluation,” says Mark Clemens, M.D., the senior author of the study...
MD Anderson researchers have discovered that metastatic cancer cells in the brain upregulate expression of the EZH2 gene to activate a previously...
Researchers at MD Anderson have discovered that cancer-associated fibroblasts (CAF) help fuel the growth of breast tumors. Their findings...
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer types. Breast cancers related to a BRCA mutation are also more likely to be triple-negative breast cancer (TNBC), which can be more aggressive and difficult to treat.
Previous studies have shown that targeted drug therapies may be more effective in treating BRCA-associated breast cancers than...
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...
A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...